Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?

Schwalsberger, Karin; Reininghaus, Bernd; Reiter, Alexandra; Dalkner, Nina; Fleischmann, Eva; Fellendorf, Frederike T.; Platzer, Martina; Reininghaus, Eva

doi:10.24869/psyd.2022.219

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] However, Schwalsberger et al purported that no evidence-based recommendations for sex-based differences in significant depression exist and that pharmaceutical treatment approaches are sporadically based on trial and error. [17] Sramek et al purported a lack of consensus as to whether there are sex-related differences in the effectiveness of antidepressants despite it being well-known that major depressive disorder is more prevalent in women. [18] An analytical study conducted by Kornstein et al and replicated by Young et al examined gender differences in responses to a selective serotonin reuptake inhibitor compared to a tricyclic antidepressant in treating chronic depression.…”

Section: Biomolecular Psychological Perspectivementioning

confidence: 99%

Targeting the female endocannabinoid system: A CAM intervention addressing behavioral nutrition and treating depression in women with T2DM

Persad¹

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

The following disquisition utilizes the principles of biomolecular psychology to examine the biopsychological efficacy of nutraceutical medications targeting the Female Endocannabinoid System (FECS), particularly concerning Type 2 diabetic (T2DM) women suffering from depression. Theoretical frameworks of psychoneuroimmunology linked with endocannabinoid deficiency theories and behavioral nutrition provide evidence for the efficacious use of Complimentary Alternative Medicine (CAM) interventions and treatments as a preferred option for women diagnosed with T2DM suffering from chronic depression. From a biomolecular perspective, the iatrogenic effects of synthetic drugs have demonstrated profound disadvantages for the female body. Future direction for research and implementation of alternative dietary plans and botanic cannabinoid supplementation for treating depression and other mood disorders associated with the imbalances of the Female Endocannabinoid System is discussed.

show abstract

Section: Biomolecular Psychological Perspectivementioning

confidence: 99%

Targeting the female endocannabinoid system: A CAM intervention addressing behavioral nutrition and treating depression in women with T2DM

Persad¹

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments

Frohman,

Nnah,

Tsirka

2023

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Cluster B personality disorders and psychotropic medications: a focused analysis of trends and patterns across sex and age groups

Lunghi,

Cailhol,

Massamba

et al. 2024

Soc Psychiatry Psychiatr Epidemiol

View full text Add to dashboard Cite

Purpose This study investigated sex and age differences in patterns of psychotropic medication use before and after the initial diagnosis of Cluster B personality disorders (PDs) and analyzed trends over time. Methods Analyzing data from the Quebec Integrated Chronic Disease Surveillance System for individuals newly diagnosed with Cluster B PD (≥ 14 years) between 2002 and 2018 and under the provincial public drug plan, we calculated yearly and monthly proportions of individuals exposed to psychotropic medications during the year before and after their diagnosis by sex and age. Robust Poisson regression models assessed the association between sex and exposure to psychotropic medications after the diagnosis of Cluster B PD. Results Among 87,778 individuals with a first Cluster B PD diagnosis (mean age: 44.5 years; 57.5% women), the proportion of users increased post-diagnosis. Notably, after diagnosis, females were more likely to receive psychiatric medications (between 78.9% and 83.7% during the study period vs. 72.8% and 76.8%). Males were less likely than females to receive antidepressants (adjusted prevalence ratio (aPR): 0.83; 99% confidence interval (CI): 0.82–0.85) and anxiolytics (aPR: 0.86; 99%CI: 0.84–0.88), whereas they had higher exposure to antipsychotics (aPR: 1.04; 99%CI: 1.02–1.06) and ADHD medications (aPR: 1.14; 99%CI: 1.07–1.2). Age-specific trends showed increased ADHD medication use among younger patients (14–24 years), and anxiolytic use predominated in those aged ≥ 65 years. Conclusions Psychotropic medication use was high among Cluster B PD patients, with differences in medication classes according to age and sex. The marked sex and age differences in psychotropic medication use among Cluster B PD patients underscore the need for a sex-sensitive and age-specific approach in psychiatric care.

show abstract

Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?

Cited by 7 publications

References 0 publications

Targeting the female endocannabinoid system: A CAM intervention addressing behavioral nutrition and treating depression in women with T2DM

Targeting the female endocannabinoid system: A CAM intervention addressing behavioral nutrition and treating depression in women with T2DM

Intersection of Sex and Depression: Pathogenesis, Presentation, and Treatments

Cluster B personality disorders and psychotropic medications: a focused analysis of trends and patterns across sex and age groups

Contact Info

Product

Resources

About